Kobayashi Pharmaceutical

Kobayashi Pharmaceutical, the Japanese maker at the center of a supplement contamination scandal linked to suspected deaths, is reportedly considering a buyout offer worth more than ¥500 billion. The move would mark a major development for a company whose reputation and finances were badly damaged by the scandal, and market watchers are closely following what a takeover could mean for its future.